CA-ANOMALI
1.8.2022 11:02:08 CEST | Business Wire | Press release
Anomali , a leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that Steve Benton has been appointed to the position of Vice President of Anomali Threat Research (ATR) and General Manager of the Anomali Belfast, Ireland Office. Benton, an experienced cyber security expert has a history of strategic advisory, intelligence sharing and coordinated response across MD, CxO, and board audiences. Benton joins Anomali during a time of rapid global expansion, to deliver guidance to global organizations on investment, strategy and making security a business enabler to rapidly address the evolving global threats of today and in the future.
“Steve brings a wealth of experience to Anomali – both in cybersecurity and in building and contributing to the wider security community. His experience and expertise spanning cyber security advisory, thought leadership, strategic development and execution will be a tremendous asset to our customers, partners, and investors,” said Mark Alba, CPO. “Steve’s extensive experience and expertise has been instrumental in helping guide global organizations on what is required to operate successfully in an ever-increasing and complex threat environment. We are very excited about Steve playing a pivotal role in how Anomali solutions can further help customers to thrive, grow and face security challenges with confidence.”
Benton has more than three decades of experience working with customers to solve their most difficult security challenges. Most recently, Benton was Deputy CISO and latterly CSO for BT where he was accountable for physical and cyber security across investment, posture, and response globally. While at BT, he built and led the Protect BT Services and Operations organization spanning intelligence, offensive security, cyber security operations, physical security operations, strategy, investigations, and incidents. In addition, he innovated proactive threat hunting and wide-ranging intelligence operations to anticipate threats, track threat actors, and their methods. An industry security expert, Benton is a contributing member of the Cyber Defenders Council, Fellow of the Chartered Institute of Information Security and a regular speaker and influencer to the i4 C level community.
“I am excited to join Anomali, the leader of threat-intelligence driven solutions, and contribute to the mission of helping organizations efficiently and effectively stop breaches and advanced adversaries,” said Benton. “As a previous customer, I leveraged the Anomali portfolio at the heart of my drive to improve security posture and disrupt threat actor activities at pace, whilst driving the democratisation of threat intelligence across the business. To know yourself and your adversaries through high fidelity, actionable intelligence, that constantly informs your decisions and guides a dynamic security posture, is the new battleground. And I look forward to bringing my frontline operational and strategic experience to Anomali customers and partners. With cyberattacks on the rise, ever more complex and multidimensional, organizations require an integrated XDR solution to tell them who they are up against, why, when they are being attacked, and how to accelerate their multifaceted response. The Anomali Platform greatly enhances an organization’s ability to address newly detected attacks, cresting threats and subsequent future attacks. Put simply, confidence in the face of uncertainty.”
For more information, visit:
www.anomali.com
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management (the “X”) and refined by artificial intelligence, The Anomali Platform, an XDR solution, delivers unique proprietary capabilities that correlate the largest repository of global intelligence with telemetry from customer-deployed security solutions. This combination empowers security operations teams to detect threats with precision, optimize response, achieve resiliency, and ultimately stop attackers and breaches. Our SaaS-based solutions easily integrate into existing security tech stacks through native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses and large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, businesses, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220729005511/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
